BioReference debuts NGS tumor profiling assay

By The Science Advisory Board staff writers

September 2, 2020 -- Opko Health's BioReference Laboratories and its specialty oncology division GenPath have launched a next-generation (NGS) assay that enables DNA mutational profiling of tumor samples.

OnkoSight advanced NGS testing provides targeted gene content that is aligned with the latest guidelines from the National Comprehensive Cancer Network and the World Health Organization and provides insight into the most common types of cancer.

The assay panel also includes information on key biomarkers like tumor mutation burden and tumor-only microsatellite, which are necessary when profiling advanced-stage tumor malignancies.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.